At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 66 enrolled
Drug / intervention
LYS006 20 mg +2 moredrug
Likely dose
LYS006 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Subject and Investigator Blinded, Placebo Controlled, Multi-center Study in Parallel Groups to Assess the Efficacy and Safety of LYS006 in Patients With Moderate to Severe Inflammatory Acne
In Brief
A Phase 2 clinical trial evaluating LYS006 20 mg, LYS006 2 mg, and 1 other intervention for Inflammatory Acne. Completed, enrolled 66 participants across 17 sites in 6 countries.
Detailed Summary
The main purpose of this study is to assess preliminary efficacy and safety of LYS006 in patients with moderate to severe inflammatory acne and to determine if LYS006 has an adequate clinical profile for further clinical development.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInflammatory Acne
CountriesCzechia, France, Germany, Hungary, Netherlands, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedApr 2018
Enrollment StartSep 2018
Primary CompletionFeb 2022
Study CompletionMar 2022
TodayJul 2026
First PostedApr 13, 2018
Enrollment StartSep 10, 2018
Primary CompletionFeb 24, 2022
Study CompletionMar 9, 2022
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 8.2 years ago
Interventions
LYS006 20 mgdrug
LYS006 20 mg, capsules, oral administration, BID, for 12 weeks
LYS006 2 mgdrug
LYS006 2 mg, capsules, oral administration, BID, for 12 weeks
Placebodrug
Matching placebo, capsules, oral administration, BID, for 12 weeks